Whilst it’s varied over time, NICE has been getting faster at publishing final Single Technology Appraisal (STA) guidance (see figure 1). The most recent public data available from the Department of ...

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”. The ...

The final Derby de la Cote d’Azur this season takes place on Sunday as Nice seek their first Ligue 1 home triumph of 2026 when they welcome Monaco to Allianz Riviera in Southern France. Les Aiglons ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...